🔗 Share this article WHO Issues Warning Over Critical Lack of Weight-Loss Medications Under 10% of people that would benefit from weight-loss injections such as Wegovy have access to them, states the World Health Organization as it releases its initial advice on the drugs. With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging broader and more equitable availability to this class of drugs. Based on projections, more than two billion will be obese by 2030 without intervention. "The new guidelines acknowledges that excess weight is a long-term condition that can be treated with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to broad availability to the jabs that can help people shift significant weight, says the body. Weight-Loss Drug Supply Crisis Even in the current best projected scenario, the production of these medications could only cover approximately 100 million people – less than 10% of those who need them, per the WHO. The recommendation encourages governments and firms to widen availability, via measures including patent sharing. A patent on the active ingredient – the primary component of the drug Wegovy – is set to lapse in several nations in 2026. The Way Obesity Jabs Operate GLP-1 drugs mimick a natural hormone to delay gastric emptying, suppress the appetite and boost satiety so users eat less. Individuals typically start to lose weight within a few weeks of beginning the regular doses. Evidence indicates patients may regain a significant portion after a year of halting the medication, as their usual appetite return. To be carrying excess weight raises your chance for contracting medical conditions, like diabetes, heart disease, brain attack, and certain malignancies. Obesity concerns individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, as per the WHO.
Under 10% of people that would benefit from weight-loss injections such as Wegovy have access to them, states the World Health Organization as it releases its initial advice on the drugs. With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging broader and more equitable availability to this class of drugs. Based on projections, more than two billion will be obese by 2030 without intervention. "The new guidelines acknowledges that excess weight is a long-term condition that can be treated with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to broad availability to the jabs that can help people shift significant weight, says the body. Weight-Loss Drug Supply Crisis Even in the current best projected scenario, the production of these medications could only cover approximately 100 million people – less than 10% of those who need them, per the WHO. The recommendation encourages governments and firms to widen availability, via measures including patent sharing. A patent on the active ingredient – the primary component of the drug Wegovy – is set to lapse in several nations in 2026. The Way Obesity Jabs Operate GLP-1 drugs mimick a natural hormone to delay gastric emptying, suppress the appetite and boost satiety so users eat less. Individuals typically start to lose weight within a few weeks of beginning the regular doses. Evidence indicates patients may regain a significant portion after a year of halting the medication, as their usual appetite return. To be carrying excess weight raises your chance for contracting medical conditions, like diabetes, heart disease, brain attack, and certain malignancies. Obesity concerns individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, as per the WHO.